drugset

drugset / Trial / NCT02586350

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

NCT02586350 ↗

Phase 2/3 Completed 91 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.

Timeline

Start: 2015-07
Primary completion: 2018-09-30
Completion: 2018-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	—	Oral

Indications